Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tuberculosis (TB) Screening for the Diagnosis of Latent TB in Immunocompromised Populations

This study has been completed.
Sponsor:
Collaborator:
Oxford Immunotec
Information provided by:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT00134342
First received: August 22, 2005
Last updated: December 22, 2010
Last verified: July 2005

August 22, 2005
December 22, 2010
January 2005
April 2005   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00134342 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Tuberculosis (TB) Screening for the Diagnosis of Latent TB in Immunocompromised Populations
A Comparison of Traditional Tuberculosis Screening Methods With the T-SPOT TB Test for the Diagnosis of Latent Tuberculosis Infection in Immunocompromised Populations

The tuberculin skin test (TST) has been the gold standard for diagnosing latent tuberculosis for almost 100 years. While this test performs reasonably well in healthy, non-bacille Calmette-Guerin (BCG) vaccinated populations, it is believed to perform less well in patients who do not have intact cellular immune systems (immunocompromised).

The investigators hypothesize that a new test, the T-SPOT TB ELISPOT test will provide a more accurate measurement of latent infection in immunocompromised people. This study will compare the TST to the T-SPOT TB ELISPOT test, and to the results of an expert physician diagnostic panel.

Main Study Question:

We propose to investigate the correlation between the traditional TST-based method of screening for latent tuberculosis infection in specific immunocompromised populations as recommended by Canadian and American standards: the T-SPOT TB ELISPOT test: and an expert tuberculosis physician panel incorporating the Mantoux test, a risk factor survey, and a chest radiograph.

Secondary Study Question:

In a subset of patients who have tested positive on both the Mantoux and T-SPOT ELISPOT tests prior to undergoing additional immune suppression i.e., patients pre-bone marrow transplant and rheumatology patients pre-receipt of anti-TNF alpha therapy or high dose corticosteroids, we propose to repeat the T-SPOT ELISPOT and Mantoux after immune suppression to assess the development of cutaneous anergy.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

patients with endstage renal disease

Tuberculosis
Other: T-SPOT TB ELISPOT test
ELISPOT test for detecting T cell responses to tuberculosis antigens.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
203
April 2005
April 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

Inclusion criteria for the study are broad.

  • Participants can be enrolled regardless of race, gender, risk of exposure to TB, metabolic disorders or coinfection with non-TB agents.
  • Only participants who have provided written informed consent will be included.
  • Patients belonging to the four following groups will be considered eligible for tuberculosis screening and inclusion in the T-SPOT ELISPOT study:

    • Patients with end stage renal disease receiving hemodialysis or peritoneal dialysis;
    • Recipients of solid organ transplants;
    • Recipients of, or candidates for, an allogeneic stem cell transplant for hematologic malignancies;
    • Patients with rheumatologic diseases (e.g., systemic lupus erythematosus [SLE], rheumatoid arthritis, psoriasis) who are receiving, or about to receive, immunosuppressive therapy, including corticosteroids and anti-TNF alpha inhibitors.

Exclusion Criteria:

  • Individuals who have not signed an informed consent
  • Hemophiliacs or individuals who, on the advice of the enrolling physician, may otherwise be at increased risk of an adverse reaction to venipuncture or tuberculin skin test administration
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00134342
04-0702-AE
No
Nial Ferguson, Oxford Immunotec
University Health Network, Toronto
Oxford Immunotec
Principal Investigator: Michael Gardam, MD University Health Network, University of Toronto
University Health Network, Toronto
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP